The company secures a Beta (Market Risk) of 0.0, which conveys not very significant fluctuations relative to the market. the returns on MARKET and Marizyme are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak
Strong
Over the last 90 days Marizyme has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Marizyme is not utilizing all of its potentials. The latest stock price disarray, may contribute to short-term losses for the investors. ...more
Begin Period Cash Flow
2.9 M
Marizyme
Marizyme Relative Risk vs. Return Landscape
If you would invest 0.03 in Marizyme on July 30, 2025 and sell it today you would earn a total of 0.00 from holding Marizyme or generate 0.0% return on investment over 90 days. Marizyme is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Marizyme, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
Expected Return
Risk
Marizyme Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Marizyme's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Marizyme, and traders can use it to determine the average amount a Marizyme's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
Best Portfolio
Best Equity
Good Returns
Average Returns
Small Returns
Cash
Small Risk
Average Risk
High Risk
Huge Risk
MRZM
Based on monthly moving average Marizyme is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Marizyme by adding Marizyme to a well-diversified portfolio.
Marizyme Fundamentals Growth
Marizyme Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Marizyme, and Marizyme fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Marizyme Pink Sheet performance.
By examining Marizyme's fundamental ratios, stakeholders can obtain critical insights into Marizyme's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Marizyme is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Marizyme, Inc., a life science company, engages in the development and commercialization of medical technologies business. Marizyme, Inc. was incorporated in 2007 and is based in Jupiter, Florida. Marizyme operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 11 people.
Things to note about Marizyme performance evaluation
Checking the ongoing alerts about Marizyme for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Marizyme help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Marizyme generated a negative expected return over the last 90 days
Marizyme has some characteristics of a very speculative penny stock
The company reported the previous year's revenue of 210.28 K. Net Loss for the year was (11 M) with profit before overhead, payroll, taxes, and interest of 129.93 K.
Marizyme currently holds about 2.04 M in cash with (5.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.05, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Evaluating Marizyme's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Marizyme's pink sheet performance include:
Analyzing Marizyme's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Marizyme's stock is overvalued or undervalued compared to its peers.
Examining Marizyme's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
Evaluating Marizyme's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Marizyme's management team can help you assess the Company's leadership.
Pay attention to analyst opinions and ratings of Marizyme's pink sheet. These opinions can provide insight into Marizyme's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Marizyme's pink sheet performance is not an exact science, and many factors can impact Marizyme's pink sheet market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
Other Information on Investing in Marizyme Pink Sheet
Marizyme financial ratios help investors to determine whether Marizyme Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Marizyme with respect to the benefits of owning Marizyme security.